The Efficacy of Cancer Immunotherapies Is Compromised by Infection.

infects the gastric mucosa of a large number of humans. Although asymptomatic in the vast majority of cases, infection can lead to the development of peptic ulcers gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Using a variety of mechanisms, locally suppresses the function of the host immune system to establish chronic infection. Systemic immunomodulation has been observed in both clinical and pre-clinical studies, which have demonstrated that infection is associated with reduced incidence of inflammatory diseases, such as asthma and Crohn's disease. The introduction of immunotherapies in the arsenal of anti-cancer drugs has revealed a new facet of -induced immune suppression. In this review, we will describe the intimate interactions between and its host, and formulate hypothtyeses describing the detrimental impact of infection on the efficacy of cancer immunotherapies.